Starling Oncology director to sell 298K shares
Starling Oncology, Inc. (STLN) received a notice that director Bradford Hively plans a Rule 144 sale of up to 298,853 shares of common stock through Morgan Stanley Smith Barney LLC.
Rhea-AI Filing Summary
Starling Oncology, Inc. (STLN) received a notice that director Bradford Hively plans a Rule 144 sale of up to 298,853 shares of common stock through Morgan Stanley Smith Barney LLC. The shares have an indicated aggregate market value of $1,954,498.62, with 101,916,115 shares outstanding and an approximate sale date of August 21, 2026. The filing lists prior acquisition methods including open market purchases and restricted stock units.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Rule 144 regulatory
restricted stock units financial
Open Market Purchase financial
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction is disclosed for STLN in this Form 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.